Omega Healthcare Investors, Inc. (O2HI34) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Omega Healthcare Investors, Inc. BRL 189, price BRL 80.88, upside +133.6%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Omega Healthcare Investors, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
56‑month range R$32.10 – R$87.71 · fair‑value band R$101.37 – R$261.07 · the R$80.88 price screens below the R$188.97 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Omega Healthcare Investors in your weekly email
Every Wednesday you see whether Omega Healthcare Investors is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Omega Healthcare Investors, Inc. is a Real Estate Investment Trust. The firm is providing financing and capital to the long-term healthcare industry in the United States and the United Kingdom with a focus on skilled nursing and assisted living facilities, including care homes in the United Kingdom.
Show more
Omega Healthcare Investors, Inc. is a Real Estate Investment Trust. The firm is providing financing and capital to the long-term healthcare industry in the United States and the United Kingdom with a focus on skilled nursing and assisted living facilities, including care homes in the United Kingdom. As of September 30, 2025, Omega has a portfolio of investments that includes 1,024 operating facilities located in 42 states, the District of Columbia and the United Kingdom/Jersey (290 facilities) and operated by 88 different operators. Additionally, Omega has investments in several unconsolidated entities that own 19 facilities. As a source of capital to the healthcare industry, Omega continually evaluates the opportunities, trends and challenges affecting the industry. Our goal is to identify long-term investments in quality healthcare properties with outstanding operators that provide the most favorable risk/reward ratio to our investors. Omega Healthcare Investors, Inc. is based in Hunt Valley, United States.
Stock analysis
Omega Healthcare Investors, Inc. (O2HI34) currently trades at R$80.88, while our model-based Fair Value estimate is R$188.97, implying the stock looks roughly 57.2% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of R$295.07 per share, and 13 of the 15 models we run sit above the R$80.88 price.
Bear case: the Asset-Based group reads lowest at R$60.88, and 2 of the 15 models stay below the price. Evidence for this calculation is high.
Scenario range: R$101.37 (bear) to R$261.07 (bull), the price of R$80.88 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Real Estate sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Omega Healthcare Investors, Inc. reported revenue of $1.2B in FY2025 versus $878M in FY2022, a compound +10.7%/yr. Reported net income was $590M in FY2025, compounding +11.4%/yr from FY2022.
Key figures
Market cap R$23.9B (≈ $4.6B) · P/E ratio 7.5 · P/S ratio 3.74 · EPS (TTM) R$10.73 · Dividend yield 3.3% · Net margin 49.6% · Return on equity 12.6% · Return on assets (EBIT) 2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Real Estate peers we cover trades at −6% fair-value upside, at 134%, O2HI34 screens cheaper than that median.
Fair Value models
Bear R$101.37Fair Value R$188.97Bull R$261.07
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$6.09 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+15.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.4%
Dividend (yield on the price)3.3%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 43%
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −1.4% a year for the price and −0.1% for the forecasts.
Compare Omega Healthcare Investors, Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.REIT - Healthcare Facilities · 25 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Omega Healthcare Investors, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/O2HI34
Frequently asked questions
Is Omega Healthcare Investors, Inc. (O2HI34) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of R$188.97 versus a price of R$80.88, about +134% upside (undervalued).
What is the fair value of O2HI34?
Our model-based fair value for Omega Healthcare Investors, Inc. is R$188.97 (as of Sep 24, 2026), built from audited fundamentals. The current price: R$80.88.
What is the quality score of O2HI34?
Omega Healthcare Investors, Inc. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Omega Healthcare Investors, Inc. (O2HI34)?
Our model-based price target is the fair value of R$188.97 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario R$101.37, optimistic scenario R$261.07. It is a calculation from audited fundamentals, not an analyst target.
What is the Omega Healthcare Investors, Inc. stock forecast for 2026?
Our models put fair value at R$188.97, about +134% upside versus a price of R$80.88 (undervalued). Cautious scenario R$101.37, optimistic scenario R$261.07. The calculation is refreshed regularly with new filings.
What is the revenue of Omega Healthcare Investors, Inc. (O2HI34)?
Omega Healthcare Investors, Inc. reported trailing-twelve-month revenue of about $1.2B (latest available figure, as of Sep 24, 2026).
Does Omega Healthcare Investors, Inc. pay a dividend?
Omega Healthcare Investors, Inc. currently shows a dividend yield of about 3.31% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Omega Healthcare Investors, Inc. (O2HI34)?
For today's price to be fair in a discounted-cash-flow model, Omega Healthcare Investors, Inc. would have to grow free cash flow by +1.0 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +10.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of O2HI34 use?
Our models discount Omega Healthcare Investors, Inc. at 11.4 %: a base by market capitalisation (mid), damped by beta 0.57, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Omega Healthcare Investors, Inc. that is +1.0 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Omega Healthcare Investors, Inc. (O2HI34) delivered so far?
Over the past 3 years revenue at Omega Healthcare Investors, Inc. grew +10.7 % a year. The price currently implies +1.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Omega Healthcare Investors, Inc. (O2HI34) growing?
The median revenue growth in the sector is +1.8 % a year. That is the yardstick for the growth priced into Omega Healthcare Investors, Inc. (+1.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Omega Healthcare Investors, Inc. (O2HI34)?
The free-cash-flow yield on the price is 19.19 %: that much free cash flow Omega Healthcare Investors, Inc. produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Omega Healthcare Investors, Inc. (O2HI34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Omega Healthcare Investors, Inc. it is R$188.97 per share (as of Sep 24, 2026), against a price of R$80.88. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Omega Healthcare Investors, Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, O2HI34 trades below its calculated fair value: price R$80.88, fair value R$188.97, a gap of about +134% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of O2HI34?
No. The price is what the market pays today (R$80.88); the fair value is what the company's own numbers justify (R$188.97). For Omega Healthcare Investors, Inc. the two are R$108.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Omega Healthcare Investors, Inc. worth?
The market values Omega Healthcare Investors, Inc. at about R$23.9B (market capitalisation, as of Sep 24, 2026). Per share that is R$80.88; our models calculate a fair value of R$188.97 per share.
What do the bullish and bearish scenarios say about O2HI34?
Our models span a range for Omega Healthcare Investors, Inc.: cautious scenario R$101.37, base R$188.97, optimistic R$261.07 per share (as of Sep 24, 2026, price R$80.88). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of O2HI34?
Omega Healthcare Investors, Inc. trades at a price-to-earnings ratio of 7.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$188.97 is built from several models across several years. Other multiples: P/B 0.9, P/S 3.7, EV/EBITDA 7.8.
How solid is the balance sheet of Omega Healthcare Investors, Inc. (O2HI34)?
Balance-sheet figures for Omega Healthcare Investors, Inc. (as of Sep 24, 2026): return on equity 12.6%, debt of 0.82 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is O2HI34 from its 52-week high?
Omega Healthcare Investors, Inc. trades at R$80.88, about 8% below its 52-week high of R$87.71 and 18% above the low of R$68.61 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$188.97 is for.
Which stocks are comparable to Omega Healthcare Investors, Inc.?
From the same area (Real Estate) we also value Welltower Inc, Ventas, Inc, Healthpeak Properties, Inc, American Healthcare REIT, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Omega Healthcare Investors, Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price R$80.88, calculated fair value R$188.97 (+134%), Quality Score 48/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of O2HI34 calculated?
We run Omega Healthcare Investors, Inc. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$188.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Omega Healthcare Investors, Inc. currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Omega Healthcare Investors, Inc. (O2HI34)?
The closing price on Oct 1, 2026 was R$80.88. Our model-based fair value is R$188.97, about +134% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Omega Healthcare Investors, Inc. right now?
The price is below even our cautious bear case (R$101.37). The market is more pessimistic than our downside scenario. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (R$101.37 to R$261.07) leaves room in how you read the outcome. As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Key figures of Omega Healthcare Investors, Inc.
How large is the market capitalisation of Omega Healthcare Investors, Inc. (O2HI34)?
The market capitalisation of Omega Healthcare Investors, Inc. is R$23.9B (≈ $4.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Omega Healthcare Investors, Inc. (O2HI34)?
The price-to-sales ratio of Omega Healthcare Investors, Inc. is 3.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Omega Healthcare Investors, Inc. (O2HI34)?
Earnings per share at Omega Healthcare Investors, Inc. are R$10.73 (price ÷ EPS = P/E 7.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Omega Healthcare Investors, Inc. (O2HI34)?
The dividend yield of Omega Healthcare Investors, Inc. is 3.3% (payout 25.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Omega Healthcare Investors, Inc. (O2HI34)?
The net margin of Omega Healthcare Investors, Inc. is 49.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Omega Healthcare Investors, Inc. (O2HI34)?
The return on equity (ROE) of Omega Healthcare Investors, Inc. is 12.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Omega Healthcare Investors, Inc. (O2HI34)?
On an EBIT basis the return on assets of Omega Healthcare Investors, Inc. is 2.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Omega Healthcare Investors, Inc. (O2HI34)?
The operating margin of Omega Healthcare Investors, Inc. is 65.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Omega Healthcare Investors, Inc. (O2HI34)?
Revenue at Omega Healthcare Investors, Inc. is growing +14.3% versus a year earlier (3y avg +10.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Omega Healthcare Investors, Inc. (O2HI34)?
Earnings per share at Omega Healthcare Investors, Inc. are growing +39.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Omega Healthcare Investors, Inc. (O2HI34) carry?
The net debt of Omega Healthcare Investors, Inc. is $4.2B (fiscal year 2025, ≈ 4.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Omega Healthcare Investors, Inc. in the live analysis
One click puts Omega Healthcare Investors, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
